يعرض 1 - 10 نتائج من 35 نتيجة بحث عن '"Amy V Kapp"', وقت الاستعلام: 1.09s تنقيح النتائج
  1. 1
    Supplemental tables and figures from Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

    المؤلفون: Josep Tabernero, Andrea Pirzkall, Elicia M. Penuel, William D. Hanley, Bruce B. McCall, Roxana I. Sufan, Amy V. Kapp, Manuel Hidalgo, Andrew L. Coveler, John Bridgewater, Maria Di Bartolomeo, Mark Jeffery, Alessio Amatu, Meinolf Karthaus, Vinod Ganju, Leslie Samuel, Pilar Garcia Alfonso, Christopher Jackson, Matthew E. Burge, Michael P. Findlay, Andrew G. Hill

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ac160f71779429f6724ad8a85eb62a8
    https://doi.org/10.1158/1078-0432.22464057.v1

    أضف إلى المفضلة
  2. 2
    Data from Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

    المؤلفون: Josep Tabernero, Andrea Pirzkall, Elicia M. Penuel, William D. Hanley, Bruce B. McCall, Roxana I. Sufan, Amy V. Kapp, Manuel Hidalgo, Andrew L. Coveler, John Bridgewater, Maria Di Bartolomeo, Mark Jeffery, Alessio Amatu, Meinolf Karthaus, Vinod Ganju, Leslie Samuel, Pilar Garcia Alfonso, Christopher Jackson, Matthew E. Burge, Michael P. Findlay, Andrew G. Hill

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02b2afd34122ac04cb6d26c767b34213
    https://doi.org/10.1158/1078-0432.c.6525606

    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Randomized Phase II Study of Duligotuzumab (MEHD7945A) versus Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEGHAN Study)

    المؤلفون: Jérôme FAYETTE, Lori Wirth, Cristina Oprean, Anghel Udrea, Antonio Jimeno, Danny Rischin, Christopher Nutting, Paul M. Harari, Tibor Csoszi, Dana Cernea, Paul O’Brien, William D. Hanley, Amy V. Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan Baptist Vermorken

    المصدر: Frontiers in Oncology, Vol 6 (2016)

    مصطلحات موضوعية: EGFR, HPV, cetuximab, HER3, Nrg1, SCCHN, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

    وصف الملف: electronic resource

    Relation: http://journal.frontiersin.org/Journal/10.3389/fonc.2016.00232/full; https://doaj.org/toc/2234-943X

    URL الوصول: https://doaj.org/article/d89afeed3e904b81a4584162cf8e5c84

    Full Text Finder
    أضف إلى المفضلة
  4. 4
    Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer

    المؤلفون: Cristina Saura, Mafalda Oliveira, Valentina Gambardella, Kevin Kalinsky, Andrés Cervantes, Naoki Kotani, Ian E. Krop, Zachary William Neil Veitch, Komal Jhaveri, Dejan Juric, Erika Hamilton, Antoine Italiano, Anjali Vaze, Stephanie Royer-Joo, Katie Hutchinson, Peter Schmid, Philippe L. Bedard, Jennifer L. Schutzman, Nicholas C. Turner, Andrea Varga, Amy V. Kapp, Leslie J. Dickmann

    المصدر: Cancer Research. 80:P1-19

    مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, macromolecular substances, Palbociclib, Neutropenia, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Internal medicine, otorhinolaryngologic diseases, medicine, Dexamethasone, Chemotherapy, business.industry, Letrozole, medicine.disease, Hypokalemia, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Pharmacodynamics, medicine.symptom, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::b2b3a627abc0931cc93a4db286d0dffb
    https://doi.org/10.1158/1538-7445.sabcs19-p1-19-46

    أضف إلى المفضلة
  5. 5
    Abstract OT1-08-04: A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors

    المؤلفون: Erika Hamilton, Mafalda Oliveira, Andrés Cervantes, Amy V. Kapp, Jennifer L. Schutzman, Nicholas C. Turner, Naoki Kotani, Zachary William Neil Veitch, Ian E. Krop, Dejan Juric, Antoine Italiano, Stephanie Royer-Joo, Komal Jhaveri, Philippe L. Bedard, Anjali Vaze, Peter Schmid, Katie Hutchinson, Kevin Kalinsky, Leslie J. Dickmann, Jill Fredrickson, Andrea Varga, Valentina Gambardella, Cristina Saura

    المصدر: Cancer Research. 80:OT1-08

    مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, Cumulative dose, business.industry, Colorectal cancer, Cmax, Palbociclib, medicine.disease, Gastroenterology, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Breast cancer, Oncology, Pharmacokinetics, 030220 oncology & carcinogenesis, Pharmacodynamics, Internal medicine, Medicine, business, Adverse effect

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::fc5bf22ca7934f0794876215f24e77b3
    https://doi.org/10.1158/1538-7445.sabcs19-ot1-08-04

    أضف إلى المفضلة
  6. 6
    Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

    المؤلفون: Vinod Ganju, M. Karthaus, Alessio Amatu, Andrea Pirzkall, Amy V. Kapp, Michael Findlay, Maria Di Bartolomeo, Leslie Samuel, Manuel Hidalgo, Bruce McCall, Christopher Jackson, Roxana Ioana Sufan, Andrew L. Coveler, William D. Hanley, John Bridgewater, Matthew Burge, Elicia Penuel, Pilar García Alfonso, Andrew G. Hill, Josep Tabernero, Mark Jeffery

    المصدر: Clinical Cancer Research. 24:2276-2284

    مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Colorectal cancer, Phases of clinical research, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Progression-free survival, Cetuximab, business.industry, Cancer, medicine.disease, Rash, digestive system diseases, 030104 developmental biology, 030220 oncology & carcinogenesis, FOLFIRI, KRAS, medicine.symptom, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::ccae888b9f36e880f1895c859efd2c58
    https://doi.org/10.1158/1078-0432.ccr-17-0646

    أضف إلى المفضلة
  7. 7
    Abstract P2-09-20: Biomarker analysis of the LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) in metastatic triple-negative breast cancer (TNBC)

    المؤلفون: Marcos Vinicius Silva Oliveira, Amy V. Kapp, Wai Y. Chan, Steven Gendreau, Stina M. Singel, S-B Kim, Matthew Wongchenko, Rebecca Dent, Cristina Saura, Daniel J. Maslyar, J. Baselga

    المصدر: Cancer Research. 78:P2-09

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, First line, Ipatasertib, chemistry.chemical_compound, Paclitaxel, chemistry, Internal medicine, Medicine, Biomarker Analysis, business, Triple-negative breast cancer

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::3e760b20a9714ef4d06fc480c75fb365
    https://doi.org/10.1158/1538-7445.sabcs17-p2-09-20

    أضف إلى المفضلة
  8. 8
    Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck

    المؤلفون: Amy V. Kapp, Stephanie Royer-Joo, Lori J. Wirth, Antonio Jimeno, X. Wang, Tanguy Y. Seiwert, Jean-Pascal Machiels, Bruce McCall, Pol Specenier, Feby Mardjuadi, Elicia Penuel, Paul Clement, Andrea Pirzkall

    المصدر: Cancer. 122:3803-3811

    مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Neutropenia, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, medicine, Cisplatin, Chemotherapy, Leukopenia, business.industry, Cancer, Common Terminology Criteria for Adverse Events, medicine.disease, Carboplatin, Surgery, 030104 developmental biology, Oncology, chemistry, 030220 oncology & carcinogenesis, medicine.symptom, business, Febrile neutropenia, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::97ef0b534bb09f451e0370104e1f425f
    https://doi.org/10.1002/cncr.30256

    View record at Wiley
    أضف إلى المفضلة
  9. 9
    Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

    المؤلفون: Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko, Amy V Kapp, Wai Y Chan, Stina M Singel, Daniel J Maslyar, José Baselga, Keun Seok Lee, Hwei-Chung Wang, Antoinette Tan, Joo Hyuk Sohn, Michelino De Laurentiis, Laura Garcia Estevez, Chiun-Sheng Huang, Gilles Romieu, Michel Velez, Rafael Villanueva, Pier Franco Conte, Shaker Dakhil, Marc Debled, Antonio Gonzalez Martin, Sara Hurvitz, Jee Hyun Kim, Christelle Levy, Pedro Sanchez Rovira, Jae Hong Seo, Vicente Valero, Gregory Vidal, Andrea Wong, Mary Ann K Allison, Robert Figlin, David Chan, Shin-Cheh Chen, Yen-Hsun Chen, Melody Cobleigh, Filippo De Braud, Luc Dirix, Vincent Hansen, Anne Hardy Bessard, Nicholas Iannotti, Steven Isakoff, William Lawler, Alvaro Montaño, Mohamad Salkini, Leonard Seigel

    المساهمون: Kim, Sung-bae, Dent, Rebecca, Im, Seock-ah, Espié, Marc, Blau, Sibel, Tan, Antoinette R, Isakoff, Steven J, Oliveira, Mafalda, Saura, Cristina, Wongchenko, Matthew J, Kapp, Amy V, Chan, Wai Y, Singel, Stina M, Maslyar, Daniel J, Baselga, José, De Laurentiis, Michelino

    المصدر: The Lancet. Oncology, vol 18, iss 10

    مصطلحات موضوعية: 0301 basic medicine, Administration, Oral, Triple Negative Breast Neoplasms, LOTUS investigators, law.invention, Placebos, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Cancer, education.field_of_study, Hazard ratio, Middle Aged, Prognosis, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, Administration, Female, Survival Analysi, Drug, Human, Oral, Adult, medicine.medical_specialty, Paclitaxel, Maximum Tolerated Dose, Prognosi, Population, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Placebo, Risk Assessment, Disease-Free Survival, Drug Administration Schedule, Dose-Response Relationship, 03 medical and health sciences, Breast cancer, Double-Blind Method, Clinical Research, Internal medicine, Breast Cancer, medicine, Adjuvant therapy, Confidence Intervals, Humans, Neoplasm Invasiveness, Oncology & Carcinogenesis, education, Survival analysis, Neoplasm Staging, Proportional Hazards Models, Aged, Neoplasm Invasivene, Antineoplastic Combined Chemotherapy Protocol, Dose-Response Relationship, Drug, business.industry, Patient Selection, Evaluation of treatments and therapeutic interventions, medicine.disease, Survival Analysis, Surgery, Clinical trial, 030104 developmental biology, Proportional Hazards Model, business, Confidence Interval, Proto-Oncogene Proteins c-akt

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23bb66843d8ecfd467caeec1baf17b8a
    https://escholarship.org/uc/item/7z70q2hf

    أضف إلى المفضلة
  10. 10
    Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line

    المؤلفون: Andrew G, Hill, Michael P, Findlay, Matthew E, Burge, Christopher, Jackson, Pilar Garcia, Alfonso, Leslie, Samuel, Vinod, Ganju, Meinolf, Karthaus, Alessio, Amatu, Mark, Jeffery, Maria Di, Bartolomeo, John, Bridgewater, Andrew L, Coveler, Manuel, Hidalgo, Amy V, Kapp, Roxana I, Sufan, Bruce B, McCall, William D, Hanley, Elicia M, Penuel, Andrea, Pirzkall, Josep, Tabernero

    المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research. 24(10)

    مصطلحات موضوعية: Adult, Aged, 80 and over, Male, Leucovorin, Cetuximab, Middle Aged, Progression-Free Survival, Young Adult, Genes, ras, Treatment Outcome, Immunoglobulin G, Antineoplastic Combined Chemotherapy Protocols, Mutation, Retreatment, Biomarkers, Tumor, Humans, Camptothecin, Female, Fluorouracil, Molecular Targeted Therapy, Neoplasm Metastasis, Colorectal Neoplasms, Aged, Neoplasm Staging

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::84ecb9bbf757a2bccce18d6eaab55b4a
    https://pubmed.ncbi.nlm.nih.gov/29506988

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء